Cargando…
Advances in preclinical approaches to Chagas disease drug discovery
INTRODUCTION: Chagas disease affects 8–10 million people worldwide, mainly in Latin America. The current therapy for Chagas disease is limited to nifurtimox and benznidazole, which are effective in treating only the acute phase of the disease but with severe side effects. Therefore, there is an unme...
Autores principales: | Villalta, Fernando, Rachakonda, Girish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779130/ https://www.ncbi.nlm.nih.gov/pubmed/31411084 http://dx.doi.org/10.1080/17460441.2019.1652593 |
Ejemplares similares
-
Epitope Capsid-Incorporation: A New Effective Approach for Vaccine Development for Chagas Disease
por: Matthews, Qiana L., et al.
Publicado: (2016) -
Respiratory and Neurological Disease across Different Ethnic Groups Is Influenced by the Microbiome
por: Peace, Odiase, et al.
Publicado: (2021) -
A note on the the discovery of Chagas' disease
por: de Avila-Pires, Fernando Dias
Publicado: (2022) -
Preclinical Studies and Drug Combination of Low-Cost Molecules for Chagas Disease
por: Aguilera, Elena, et al.
Publicado: (2022) -
Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery
por: Mansoldo, Felipe Raposo Passos, et al.
Publicado: (2020)